Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer L. Crombie, Michael Dickinson, Nancy L. Bartlett et al.|Blood|2024Cited by 132
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaborationDeborah M. Stephens, John C. Byrd, Kenneth M. Boucher et al.|Haematologica|2020Cited by 36
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S. Davids, Ian W. Flinn, Owen A. O’Connor et al.|Blood Advances|2021Cited by 21
A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)Krish Patel, Gilles Salles, Jennifer L. Crombie et al.|Blood|2025Cited by 0